News
Pfizer Global Medical Grants & Partnerships is pleased to announce the latest grant opportunity with colleagues focused on Increasing Awareness & Understanding of Emerging Hemophilia Treatment ...
Pharmaceutical and biotechnology company Pfizer marks 70 years of dedication to its mission of advancing patient health in ...
Some five years into a pneumococcal vaccine patent dispute in South Korea, SK Bioscience has emerged victorious over Pfizer.
Pfizer has entered into an exclusive global licensing agreement with 3SBio to develop, manufacture, and commercialize SSGJ-707, a bispecific antibody targeting PD-1 and VEGF pathways. The therapy is ...
SK bioscience wins patent lawsuit against Pfizer over pneumococcal vaccine in Korea: Gyeonggi-do, Republic of Korea Friday, May 23, 2025, 10:00 Hrs [IST] SK bioscience, a global i ...
SK bioscience successfully developed Korea's first 13-valent pneumococcal conjugate vaccine, SKYPneumo, in 2016. However, due ...
Hosted on MSN25d
Department of Health – Abu Dhabi, Pfizer host high-level workshop to advance real world data in healthcare researchand global Pfizer RWE leaders to explore the potential of Abu Dhabi’s Trusted Research Environment in advancing scientific discovery. This initiative is part of a broader effort under the MoU to ...
CAMBRIDGE, Mass., April 28, 2025 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing integrated solutions from "Idea to IND" (I to ITM), today announced that its partner, Pfizer ...
The MoU underscores a shared commitment to strengthening Abu Dhabi’s position as a global hub for healthcare innovation ...
In an effort to offset declining COVID-19 product sales, Pfizer embarked on an aggressive acquisition strategy, purchasing Seagen, Global Blood Therapeutics, and Biohaven. While the Seagen ...
Pfizer (NYSE:PFE) is overhauling its cardiometabolic ... antagonist and pursuing external opportunities that could include partnerships or acquisitions. That strategic pivot comes as shares ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results